US Bancorp DE lowered its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 53.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 873 shares of the company’s stock after selling 983 shares during the period. US Bancorp DE’s holdings in VanEck Pharmaceutical ETF were worth $75,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of PPH. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in VanEck Pharmaceutical ETF by 117.4% in the fourth quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 200,000 shares of the company’s stock valued at $17,256,000 after purchasing an additional 108,000 shares during the period. Adamsbrown Wealth Consultants LLC increased its position in shares of VanEck Pharmaceutical ETF by 102.3% during the fourth quarter. Adamsbrown Wealth Consultants LLC now owns 149,631 shares of the company’s stock valued at $12,910,000 after acquiring an additional 75,659 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of VanEck Pharmaceutical ETF by 33.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock valued at $22,322,000 after acquiring an additional 59,025 shares during the period. Blue Chip Partners LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 4th quarter worth approximately $2,139,000. Finally, Miller Investment Management LP increased its holdings in VanEck Pharmaceutical ETF by 13.4% in the 3rd quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock valued at $19,722,000 after purchasing an additional 24,446 shares during the last quarter.
VanEck Pharmaceutical ETF Stock Up 1.6 %
Shares of NASDAQ PPH opened at $93.29 on Tuesday. The business’s 50 day moving average is $89.72 and its two-hundred day moving average is $91.08. VanEck Pharmaceutical ETF has a 52-week low of $84.48 and a 52-week high of $99.51. The firm has a market cap of $582.13 million, a price-to-earnings ratio of 30.55 and a beta of 0.72.
VanEck Pharmaceutical ETF Increases Dividend
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- Investing in Commodities: What Are They? How to Invest in Them
- Can TikTok Stock Picks Really Make You Rich?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- The “Quality” Rotation: Back to Basics Investing
- How to Most Effectively Use the MarketBeat Earnings Screener
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.